- Trial phase
- Filed/PDUFA (BLA under Priority Review, Accelerated Approval pathway)
- Time to market
- PDUFA decision expected around March 2027 (Priority Review, 6-month clock from September 8, 2026 BLA acceptance). If approved, commercial launch would follow weeks to months after.
- Why 4/10
- The next hard catalyst is the FDA PDUFA decision on del-zota's BLA under Priority Review (Accelerated Approval pathway). The exact date has not been publicly disclosed by Novartis, but with Priority Review's 6-month clock from the September 8, 2026 acceptance, a decision is expected around March 2027. For a company the size of Novartis (~$200B+ market cap), this single drug is a small part of a massive diversified pipeline, so the impact score is capped at 4.
The next catalyst is the FDA's decision on del-zota's BLA under Priority Review (Accelerated Approval pathway). Novartis has not disclosed the exact PDUFA date, but with Priority Review's 6-month clock from the September 8, 2026 acceptance, a decision is expected around March 2027. An approval would mark the first approved exon 44 skipping therapy for DMD; a Complete Response Letter would pressure the Avidity acquisition thesis and the broader neuromuscular pipeline.
Price Chart
Executive Summary
Del-zota (delpacibart zotadirsen) is a first-in-class antibody-oligonucleotide conjugate being developed by Novartis (NVS) for Duchenne muscular dystrophy patients whose mutations are amenable to exon 44 skipping (DMD44), a subset with no approved therapy. Novartis acquired the asset through its ~$12B purchase of Avidity Biosciences in October 2025. The FDA accepted the BLA for Priority Review under the Accelerated Approval pathway on September 8, 2026, supported by Phase 1/2 EXPLORE44 data showing up to 67% exon skipping and increased dystrophin expression. The exact PDUFA date has not been disclosed but is estimated around March 2027. A global Phase 3 confirmatory trial (SAFARI44) is recruiting. For Novartis, a ~$200B+ diversified pharma giant, del-zota is a small pipeline component, the stock impact of any single FDA decision is limited, though the drug is strategically important to the company's neuromuscular franchise built via the Avidity acquisition.
How It Works
Del-zota is a first-in-class antibody-oligonucleotide conjugate (AOC). Think of it as a guided delivery system: an antibody that targets a receptor found on muscle cells (transferrin receptor 1) is attached to a short piece of synthetic DNA-like material (a PMO). The antibody acts like a homing beacon, carrying the PMO payload specifically to skeletal and heart muscle cells. Once inside, the PMO performs 'exon 44 skipping', it effectively tells the cell's protein-making machinery to skip over a faulty section of the dystrophin gene, allowing the cell to produce a shortened but still functional version of the dystrophin protein that Duchenne patients lack.
Trial Status
Phase 1/2 EXPLORE44 trial (NCT05670730) completed with positive results published in The Lancet Neurology. Open-label extension (EXPLORE44-OLE, NCT06244082) ongoing. Global Phase 3 confirmatory trial SAFARI44 (NCT07587242) is currently recruiting. BLA was accepted by FDA for Priority Review under Accelerated Approval pathway on September 8, 2026.
The Two-Sided Case
Upcoming Catalysts
- FDA PDUFA decision on del-zota BLA, estimated around March 2027 (date not publicly disclosed by Novartis)
- Phase 3 SAFARI44 trial enrollment and interim data readouts
- Potential FDA Advisory Committee meeting if scheduled
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report